NRSTS2021, A Risk Adapted Study Evaluating Maintenance Pazopanib, Limited Margin, Dose-Escalated Radiation Therapy and Selinexor in Non-Rhabdomyosarcoma Soft Tissue Sarcoma (NRSTS)
Conditions
Adipocytic Neoplasm · Liposarcoma · Atypical Fibroxanthoma · Angiomatoid Fibrous Histiocytoma · Myoepithelioma · Fibrosarcoma NOS · Myxofibrosarcoma · Angiosarcoma · Osteosarcoma, Extraskeletal
Simple summaryAI-assisted
This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.
Locations
Lurie Children's Hospital of Chicago, Chicago, Illinois, United States
Contact: Study coordinator (Jennifer Reicheck, MD)Contact: Principal Investigator (Jennifer Reicheck, MD)Our Lady of the Lake Children's Hospital, Baton Rouge, Louisiana, United States
Contact: Study coordinator (Jeffrey Deyo, MD)Contact: Principal Investigator (Jeffrey Deyo, MD)Dana Farber Cancer Institute, Boston, Massachusetts, United States
Contact: Study coordinator (Natalie Collins, MD)Contact: Principal Investigator (Natalie Collins, MD)Washington University Medical Center, St Louis, Missouri, United States
Contact: Study coordinator (Amy Armstrong, MD)Contact: Principal Investigator (Amy Armstrong, MD)Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States
Contact: Study coordinator (Brian Turpin, MD)Contact: Principal Investigator (Brian Turpin, MD)St. Jude Children's Research Hospital, Memphis, Tennessee, United States
Contact: Principal Investigator (Jessica Gartrell, MD)
Study leads
Jessica Gartrell, MD
Principal Investigator
St. Jude Children's Research Hospital